CSIMarket


Trisalus Life Sciences Inc   (TLSI)
Other Ticker:  
 


 

Trisalus Life Sciences Inc

TLSI's Financial Statements and Analysis



Trisalus Life Sciences Inc increased first quarter of 2024 net loss per share of $-0.60 compare to net loss per share of $-0.05 recorded in the same quarter a year ago and improved compare to net loss per share of $-2.95 realized in previous quarter.


first quarter of 2024
Earnings Per Share Revenues
$ -0.6 $  6 Mill
$-0.55     $+6M    



Trisalus Life Sciences Inc 's Revenue rose by 0 % in first quarter of 2024 (Mar 31 2024) year on year, to $6 million and declined by -49.21 % sequentially.


Trisalus Life Sciences Inc is

More on TLSI's Income Statement



Trisalus Life Sciences Inc in the first quarter of 2024 recorded net loss of $-13.219 million, an increase from net loss of $-0.448 million in I. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-59.290 million realized in previous quarter.

More on TLSI's Growth

Trisalus Life Sciences Inc Inventories
In Mar 31 2024 company's net cash and cash equivalents decreased by $-8 million

More on TLSI's Cash flow Statement


Trisalus Life Sciences Inc does not pay out common stock dividend.

In trailing twelve-month period Trisalus Life Sciences Inc payed $ -2.58 cash per share, on a free-cash flow basis .


Tangible Book value grew to $ -1.55 per share from $ -2.88.

Company issued 13.92 million shares or 148.06 % in Mar 31 2024.


More on TLSI's Dividends

 Market Capitalization (Millions) 184
 Shares Outstanding (Millions) 23
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 24
 Net Income (TTM) (Millions $) -75
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Trisalus Life Sciences Inc does not pay out common stock dividend.

In trailing twelve-month period Trisalus Life Sciences Inc had negative $ -2.58 cash flow per share, on a free-cash flow basis .


Tangible Book value grew to $ -1.55 per share from $ -2.88.

Company issued 13.92 million shares or 148.06 % in Mar 31 2024.


More on TLSI's Balance Sheets

 Market Capitalization (Millions) 184
 Shares Outstanding (Millions) 23
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 24
 Net Income (TTM) (Millions $) -75
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Trisalus Life Sciences Inc Earnings

TriSalus Life Sciences Inc. Achieves Record Revenue of $6.457 Million in Recent Fiscal Period

TLSI, or Trisalus Life Sciences Inc., recently disclosed its revenue for the most recent fiscal period, reporting $6.457 million. However, the company also revealed a net deficit of $-13.219 million, which is a significant increase compared to the $-0.448 million deficit from the previous year.
In light of these financial results, TriSalus Life Sciences Inc., based in Denver and listed on the Nasdaq as TLSI, provided an update on its business situation. Mary Szela, the Chief Executive Officer of TriSalus, expressed pride in the company's strong start in the first quarter of 2024. They reported a remarkable 116% growth in revenues compared to the same period in 2023. Additionally, TriSalus has improved it...

Trisalus Life Sciences Inc Faces Significant Financial Downturn, Generating $5.193 Million Revenue in Q3 2023

Despite the Medical Equipment and Supplies company's revenue of $5.193 million in the third quarter of 2023, the financial performance of Trisalus Life Sciences Inc took a significant hit with a net shortfall of $-1.286 million. This stands in stark contrast to the balanced books reported in the same period of the previous year. This sudden downturn raises concerns and warrants a closer examination of the company's operations and financial health.
One possible explanation for this dire financial performance could be the mismanagement of resources and ineffective cost control measures. The company may have encountered unexpected expenses, such as soaring manufacturing costs or increased competition in the...